Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mavrilimumab - CSL/Kiniksa Pharmaceuticals

Next Previous
Drug Profile

Mavrilimumab - CSL/Kiniksa Pharmaceuticals

Alternative Names: Anti-GM-CSFR monoclonal antibody - MedImmune; CAM-3001; KPL-301

Latest Information Update: 07 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zenyth Therapeutics
  • Developer Kiniksa Pharmaceuticals; MedImmune
  • Class Anti-infectives; Anti-inflammatories; Antirheumatics; Cardiovascular therapies; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists; Granulocyte-macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell arteritis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cardiovascular disorders

Highest Development Phases

  • Phase II Giant cell arteritis
  • Phase I Cardiovascular disorders
  • Discontinued Inflammation; Rheumatoid arthritis; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 07 Apr 2025 MedImmune plans to terminates its licence for Mavrilimumab in Word in May 2025
  • 01 Feb 2025 Hangzhou Zhongmei Huadong Pharmaceutical plans to terminate its licensee for Mavrilimumab in Asia in May 2025, unless it resumes development within 60 days of notice, in which case the deal ends in April 2025
  • 01 Nov 2022 Mavrilimumab - CSL/Kiniksa Pharmaceuticals is available for licensing as of 01 Nov 2022. www.kiniksa.com 9372285

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top